UNSPSC 51152076: Mivacurium chloride

This classification denotes a muscle relaxant with the molecular formula C58H80N2O14.2Cl, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 600ZG213C3, chemically known as (r)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (e)-4-octenedioate (2:1) but more generally known as mivacurium chloride, which bears U.S. National Institutes of Health Compound Identifier 5281080.

UNSPSC 51152076 Mivacurium chloride is a Commodity code that nominally describes a specific neuromuscular blocking agent used in anesthesia, but recent state and local procurement activity under this code shows a mismatch: the opportunities actually posted are for naloxone (an opioid antagonist) and pharmacy benefit management systems, neither of which align with the code's stated pharmaceutical product. The source shows minimal relevant recent activity tied to mivacurium chloride itself, and the two opportunities tagged to this code diverge significantly from its nominal scope.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a market intelligence exercise that precedes formal competitive procurement. Neither opportunity addresses mivacurium chloride procurement. The code appears to see little activity aligned with its actual product definition among state and local buyers, and business development professionals should verify whether this classification reflects an ongoing data or tagging issue before committing pursuit resources.